Contract Manufacturing

Cell Therapies has supported clinical trials for over 20 years, including Australia’s first CAR-T clinical trial. Our manufacturing systems are designed to adapt phase-appropriate controls, ensuring regulatory compliance while maintaining production flexibility. With Australia’s world-class clinical infrastructure, top-tier CROs, and access to the R&D Tax Incentive, we help clients open clinical trials in Australia quickly and efficiently, while generating data supportive of global filings.

Our 13-suite Melbourne facility includes three high-throughput commercial-grade suites capable of delivering thousands of cell therapy doses annually. CTPL has supported commercial product launches and is licensed by the TGA and aligned with FDA and EMA GMP requirements. Our Pharma 4.0 digital infrastructure ensures traceability, lowers COGS, and accelerates turnaround times. Robust ESG frameworks and ISO accreditations position Cell Therapies as a low-risk, high-compliance partner for APAC commercial supply.

Our phase-appropriate PD services are built to de-risk CMC and scale-up challenges. We specialise in flexible early-stage platforms and late-stage cost optimisation. Using closed systems (e.g., Cocoon, CliniMACS Prodigy) and PAT tools (e.g., in-line flow cytometry), we optimise processes that are scalable, reproducible, and audit-ready.